VRC01LS: Phase I started

Xencor said that the NIH began an open-label, U.S. Phase I trial to evaluate IV and subcutaneous VRC01LS in about 40 healthy volunteers. Subjects will receive single doses of 5, 20 or 40 mg/kg IV or 5...